Dockrell, H M; Brahmbhatt, S; Robertson, B D; Britton, S; Fruth, U; Gebre, N; Hunegnaw, M; Hussain, R; Manadhar, R; Murrillo, L; Pessolani, M C; Roche, P; Salgado, J L; Sampaio, E; Shahid, F; Thole, J E; Young, D B (2000) Diagnostic assays for leprosy based on T-cell epitopes. Leprosy review, 71 Sup. S55-8; discussion S58. ISSN 0305-7518

Downloaded from: http://researchonline.lshtm.ac.uk/19718/

DOI:

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the publishers
Diagnostic assays for leprosy based on T-cell epitopes

H. M. DOCKRELL,1* S. BRAHMBHATT,1 B. D. ROBERTSON,2 S. BRITTON,3 U. FRUTH,4 N. GEBRE,5 M. HUNEGNAW,1 R. HUSSAIN,5 R. MANADHAR,6 L. MURRILLO,1 M. C. V. PESSOLANI,8 F. ROCHE,6 J. L. SALGADO,8 E. Sampaio,8 F. SHAHID,5 J. E. R. THOLE,** & D. B. YOUNG2

1Immunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK, 2Infectious Diseases and Microbiology, Imperial College School of Medicine, St Mary’s Campus, London, UK, 3Armauer Hansen Research Institute, Addis Ababa, Ethiopia, 4Vaccines and Biologicals, World Health Organization, Geneva, Switzerland, 5Microbiology Department, Aga Khan University, Karachi, Pakistan, 6Anandaban Leprosy Hospital, Kathmandu, Nepal, 7Instituto de Immunologia, Bogota, Colombia and 8Leprosy Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil

Summary

To date, only a limited number of antigens have been described as specific for Mycobacterium leprae, and in many cases, homologues have subsequently been shown to exist in mycobacteria such as M. avium and M. intracellulare. A Leprosy Synthetic Peptide Skin Test Initiative was established by the Steering Committee on the Immunology of Mycobacteria of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, to investigate the potential of synthetic peptides that encode T-cell epitopes as diagnostic tools, which could be used to develop a skin-test reagent specific for leprosy. Such M. leprae-specific peptides should have unique amino acid sequences, or significant sequence-dissimilarity from those in other mycobacteria. Synthetic peptides, 15 amino acids long, were synthesised from 33 genes or open reading frames within the M. leprae genome. Tuberculoid leprosy patients from four leprosy-endemic countries, Brazil, Ethiopia, Nepal and Pakistan, were tested as subjects known to have been infected with M. leprae, and to make good T-cell responses to antigens of M. leprae; UK blood donors were used as non-exposed or non-infected subjects. Peptides inducing potentially specific responses in leprosy patients and not in UK controls, and those

*Correspondence to: H. M. Dockrell, Immunology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK

**Current address: Department of Bacteriology, ID-Lelystad, Lelystad, The Netherlands
inducing cross-reaction responses, present in both leprosy patients and non-exposed, non-infected controls, were identified. A difference from the equivalent *M. tuberculosis* sequence of five or more amino acid residues did not, by itself, identify peptides that were *M. leprae*-specific, suggesting that many of these peptides may have homologues in environmental mycobacteria. To date, this approach has identified a number of peptides with greater than 90% specificity and 19–47% sensitivity, which are undergoing further specificity-testing. Such peptides would have great potential as T-cell reagents with which to monitor exposure to *M. leprae* within communities, formulated either as skin-test reagents, or as antigens for tests in vitro.

To be specific for *Mycobacterium leprae*, a peptide epitope must have a unique sequence of amino acids, not found in other mycobacteria or other infectious agents, or a significant degree of sequence-dissimilarity from the equivalent sequence in other mycobacteria. The peptide should be recognized by T cells from subjects known to be infected with *M. leprae*, such as patients with tuberculoid leprosy, and should not be recognized by those infected with other mycobacteria such as *M. tuberculosis*. *M. leprae*-specific peptides could be used to confirm early cases of leprosy, in whom diagnosis is often difficult, but would not be useful for the diagnosis of patients with multibacillary lepromatous disease, as these individuals mount weak or negligible T-cell responses. The peptide should also be recognised more strongly by T cells from subjects living in areas highly endemic for leprosy than by T cells from those living in areas of low prevalence. If such *M. leprae*-specific peptides were identified, they could be used to monitor the degree of exposure to leprosy within different communities, to aid leprosy control programmes to target their efforts in areas in which contact with *M. leprae* is more common.

Peptides 15 amino acids long were selected, using FINDPATTERNS and Epimer, from the genome of *M. leprae*, based on the presence of three or more HLA-DR binding-motifs, and synthesized. Peptides that bind to more than one HLA type would make better diagnostic reagents, as they would have the ability to be presented by antigen-presenting cells in a larger proportion of the population. However, even using such genetically permissive or ‘promiscuous’ peptides, it is likely to be necessary to use a pool of peptides, to ensure that all individuals from different ethnic groups, with different HLA types, could respond.

Tuberculoid leprosy patients were used as a group of subjects known to be infected with *M. leprae*, and known to make good T-cell responses to *M. leprae* and its antigens. Healthy staff members, who had worked closely with leprosy patients over many years without developing the disease, were also used, as such subjects, who are actually contacts to patients with leprosy, are known to show very strong T-cell responses. The leprosy patients and contacts were recruited in four leprosy-endemic countries, Brazil, Ethiopia, Nepal and Pakistan, in order that peptides capable of inducing T-cell responses in different ethnic groups might be identified. As non-exposed subjects, blood-bank donors in the UK were used, as it is extremely unlikely that any of these subjects would have visited a leprosy-endemic country, or have been exposed to *M. leprae*.

To date, 81 peptides from 33 genes have been tested for their ability to induce lymphocyte proliferation and secretion of interferon-γ (IFNγ) in standard human peripheral blood mononuclear cell (PBMC) cultures. Although most cultures showing good IFNγ-production also gave a proliferative response, secretion of IFNγ proved a more sensitive assay for detecting T-cell responses to peptides than did lymphocyte proliferation. This is likely the result of accumulation of IFNγ over the 6-day assay period, whereas lymphocyte proliferation is measured only overnight, the cultures being pulsed with tritiated thymidine on day 5.
Intracellular cytokine staining was performed in peptide-stimulated cultures from UK subjects to confirm that the majority of the cells making IFNγ were T cells.

Peptides showing greater responses in the *M. leprae*-infected or exposed groups than in the UK non-exposed group were identified, but other peptides gave equivalent responses in both groups. Analysis of the peptide sequences indicated that many of the peptides inducing good T-cell responses in the non-exposed UK donors had similar sequences in *M. leprae* and *M. tuberculosis*. Comparison of the 15 peptides tested to date which differed by five or more amino acid residues from those in the equivalent *M. tuberculosis* sequence showed that eight peptides had a specificity of 90% or greater, as defined by the IFNγ-test in the UK non-exposed group. The sensitivities to these peptides varied, usually being greater among leprosy-contacts than among tuberculoid leprosy patients. No peptide induced positive responses in all of the *M. leprae*-infected or exposed subjects, so that a number of peptides would need to be pooled to provide a reagent capable of inducing T-cell reactivity in the majority of subjects of any ethnic group. It was interesting that a difference of five or more amino acids residues from those in *M. tuberculosis* did not by itself predict *M. leprae* specificity; although the position of such amino acid changes relative to the T-cell contact residues will be critically important, it is also possible that there may be homologous epitopes within other mycobacteria such as *M. avium*, for which the full genome sequence is not yet known. Many of the peptides that induced the strongest T-cell responses in both *M. leprae*-infected and exposed subjects as well as the UK controls had very similar or identical sequences in *M. leprae* and *M. tuberculosis*. This suggests that T cells may have been strongly primed or boosted to such epitopes by vaccination with *M. bovis* BCG, or by contact with the equivalent conserved epitopes within environmental mycobacteria.

One finding of interest was the detection of strong T-cell responses to peptides from open reading frames or genes of *M. leprae* not previously known to be T-cell antigens. This suggests that the repertoire of T-cell antigens recognized during *M. leprae* infection may be much broader than had previously been thought. Many of these genes are predicted to encode enzymes involved in housekeeping or general metabolic functions, genes the structure of which might be relatively conserved. Ongoing testing of the lead peptides identified to date will include their testing with PBMC from patients with pulmonary tuberculosis; ideally, testing with PBMC from patients infected with other mycobacteria such as *M. avium* should also be performed. The peptides must also be tested with PBMC from control subjects in the various leprosy-endemic countries.

The *M. leprae* genome is now thought to contain as many as 100 genes not present in *M. tuberculosis*, which might therefore be *M. leprae*-specific genes. Peptides from these sequences should therefore be tested as a high priority. The current approach, using the presence of multiple HLA-DR binding motifs, has proved to be capable of predicting peptides that induce T-cell responses in infected subjects. It may therefore be an efficient strategy to select for testing peptides containing HLA-DR binding motifs within *M. leprae*-specific genes. Another approach would be to make overlapping peptides that span the full sequences of these genes, or at least of selected genes. This approach may identify additional T-cell epitopes, which, however, might lack the ability to be recognized by T cells from subjects belonging to different ethnic groups. A third strategy would be to express the *M. leprae*-specific genes as recombinant antigens, and to map T-cell peptide epitopes only within those antigens that give the strongest and most specific responses.

In summary, the work performed to date by this strategic Task Force has shown that a multicentre, co-ordinated approach using peptides predicted to contain three or more HLA-
DR binding-motifs can identify T-cell epitopes which are recognized by significant proportions of *M. leprae*-infected or exposed subjects. Further specificity testing of these peptides is now required, using samples of blood from patients infected with *M. tuberculosis*. A similar approach could be used to identify CD4 T-cell epitopes within genes present in *M. leprae* but absent from *M. tuberculosis*, which might have greater specificity. Such T-cell reagents could be used as research tools, to develop assays for early diagnosis, or to monitor exposure to *M. leprae* within leprosy-endemic countries.

Acknowledgements

This study was supported by a grant from the IMMYC Steering Committee of the World Health Organisation.

References


DISCUSSION

Professor Modlin: If I remember correctly, in our studies of the 10 kDa antigen, we found that only two differences in the amino acid sequence of certain peptides determined specificity for *M. leprae* or *M. tuberculosis*. It might be that some peptides with fewer than five mismatches would be useful, if the mismatches occur in the area of the T-cell-receptor contact site.

Dr Dockrell. I agree. Only a single amino acid mismatch in a critical position might be enough to change the specificity of a peptide. The IMMYC-sponsored programme has an inventory of 110 peptides that have not yet been tested, and I have just spent some time in Stewart Cole’s laboratory, seeking means of predicting activity and specificity.

Professor Britton: Do the peptides that you’ve tested include a range of HLA haplotypes? And have there been differences of reactivity to the peptides in different populations? We found a number of peptides to which Australians reacted but Nepalese did not. One of the strengths of your approach is that you are testing the peptides on two different continents among a variety of population groups; this is the correct approach.

Dr Dockrell: Some of the peptides elicited a strong response in Brazil and not in Pakistan, or in Pakistan but not in Ethiopia. This approach presupposes the use of a pool of peptides with varying HLA specificity. Unfortunately, we have been unable to HLA-type donors in the
leprosy-endemic areas. We did type the donors in the UK; however, the results were not very useful. Many with the corresponding HLA type responded, but not all, and some with another HLA type responded.

**Dr Klatser:** Can you explain the fact that some of the peptides elicit stronger reactions among contacts than among leprosy patients?

**Dr Dockrell:** Most of the contacts were staff employed in leprosy treatment centres for many years who have not become ill. Such individuals have been noted by many workers to have very strong T-cell responses.

**Dr Kaplan:** You don’t know which sub-set of lymphocytes responds. NK cells produce a great deal of IFNγ, which will remain in the supernatants for 6 days. The early NK-cell response from the normal donors would be detected in your system, and be indistinguishable from an antigen-specific response.

**Dr Dockrell:** In the UK, we have examined the T-cell profile with intracellular cytokine staining. The responding cells appear to be CD4. I believe that strong responses represent T-cell responses; I agree, that, in the case of weaker responses, we may be measuring a contribution by NK cells. Because not all donors respond, one must attribute the response to T-cells or invoke antigen-specificity on the part of NK cells.

**Dr Kaplan:** The cultures accumulate IFNγ for the 6 days of the incubation, during which the IFNγ does not decay. Intracellular cytokine staining shows the cellular profile at the moment. Depending upon the time at which you carry out the staining, you could measure IFNγ produced by cells that are no longer present in the culture.

**Professor Modlin:** Dr Kaplan, do you suggest that the peptides stimulate the NK cells to produce IFNγ?

**Dr Kaplan:** NK-cells are stimulated to produce IFNγ by cytokines IL-2, IL-12, IFNγ and TNF that are produced by bystander T-cells and monocytes. Analysis by FACS has shown that, at certain intervals, as many as 50% of the IFNγ-producing cells are CD3-minus.

**Professor Modlin:** In the final analysis, then, it is antigen-specific T-cells that trigger a non-specific NK-cell response.

**Dr Kaplan:** Production of IL-12 by monocytes is not antigen-specific. My point is that one must seek an explanation for the observation that individuals whom we suppose not to be sensitized respond strongly. I contend that we simply don’t know which cell is responding.

**Dr Dockrell:** In the situation of UK blood donors who respond strongly to some of the peptides, we are not certain that the peptides are specific to *M. leprae.*